Antibody-cytokine fusion protein combining PD-1 and IL-2
Development targeting solid tumors

On August 19, LG Chem announced that it will begin preclinical studies on 'GNV205', a next-generation immuno-oncology candidate for solid tumors introduced from the biotech company Geneuve.


Previously, in September of last year, LG Chem signed an agreement with Geneuve to secure exclusive global rights for the development and commercialization of GNV205. According to this agreement, LG Chem paid an upfront fee and will provide milestone payments and sales royalties according to the future development and commercialization stages.

LG Chem Corporate Logo Image. LG Chem

LG Chem Corporate Logo Image. LG Chem

View original image

GNV205 is an antibody-cytokine fusion protein that combines a PD-1 monoclonal antibody, which blocks immune-suppressive signaling, with the immune-activating cytokine IL-2 (interleukin-2).


GNV205 is designed to optimize its activity in the acidic tumor microenvironment. By allowing IL-2 to act selectively around cancer cells, it aims to enhance the immune response while reducing the systemic toxicity of IL-2.


LG Chem plans to evaluate the development potential of GNV205 for patients who do not respond sufficiently to existing immuno-oncology therapies or who have developed resistance to them. Through this preclinical study, the company will confirm the efficacy and safety of the candidate in solid tumors.


LG Chem is securing anticancer drug candidates through open innovation both domestically and internationally and is enhancing its own commercialization capabilities. With this agreement, the company also intends to pursue the global development of a candidate identified by a domestic biotech firm. Founded in 2016, Geneuve is a biotech company developing innovative anticancer and central nervous system drugs based on its new drug development platform.



Son Jiwoong, Head of Life Sciences at LG Chem, stated, "LG Chem plans to consistently expand its anticancer drug portfolio by balancing in-house research and development with the adoption of innovative external technologies," adding, "This collaboration is significant in that it expands innovative assets discovered by domestic biotechs into a next-generation global anticancer portfolio."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing